FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:204-205 July 15, 1993 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Clozapine appears to induce two clinically distinct types of neutropenia; these are the basis for the study by Alvir et al., reported in this issue of the Journal¹. One is a mild-to-moderate neutropenia (absolute neutrophil count, 500 to 1500 per cubic millimeter) that occurs in 1.5 to 2.0 percent of patients receiving clozapine. This form of neutropenia is probably due to premature destruction in blood or spleen, since abundant myeloid maturation is evident in the marrow. When clozapine is discontinued, recovery is rapid, within three to seven days, and patients remain asymptomatic.

The second type of neutropenia is more . . . [Full Text of this Article]

References

This article has been cited by other articles:

• DUNK, L. R., ANNAN, L. J., ANDREWS, C. D. (2006). Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br. J. Psychiatry 188: 255-263 [Abstract] [Full Text]  
• Williams, D. P., Pirmohamed, M., Naisbitt, D. J., Uetrecht, J. P., Park, B. K. (2000). Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine. Mol. Pharmacol. 58: 207-216 [Abstract] [Full Text]  
• Guith, D. M. (1996). Clozapine: Serious Adverse Side Effects, Drug Interactions, and Other Complications of Therapy. Journal of Pharmacy Practice 9: 118-129 [Abstract]